Fixkoh Airmaster Case Study

In an independent, peer reviewed case study published in Pharmacy Management Journal,1 a Health Board facilitated a change in medication to the Fixkoh Airmaster (fluticasone/salmeterol dry powder inhaler) range.

saving the Health Board approximately £100,000 per year

Summary

This project facilitated a change in medication to Fixkoh Airmaster dry powder inhaler range for over 900 patients, achieving a 90% success rate (against a target of 75%) and saving the Health Board approximately £100,000 per year (the annualised saving at the conclusion of the project).

Fixkoh Airmaster facilitated the possibility of moving a significant number to a single device type

Background

The Health Board had previously not been inclined to move patients in this cohort due to lack of choice of equivalent strengths of alternative inhalers. Fixkoh Airmaster facilitated the possibility of moving a significant number to a single device type across all three strengths of the inhaler range (mcg: Salmeterol/Fluticasone – 50/100, 50/250, 50/500).

Impact on pharmacotherapy workload

Impact on pharmacotherapy workload

An important factor in the decision to proceed was the Health Board’s commitment to pharmacotherapy, which prioritises workforce issues and support for GP workloads, as well as achieving cost efficiencies. Fixkoh Airmaster was seen by the Health Board as supportive of this objective due to potential cost savings, coupled with relatively low patient numbers which would not significantly impact on the existing pharmacotherapy workload.

Few objections were received from patients

Patient acceptability

Demonstration inhalers were offered to patients and also provided to community pharmacies for patient assistance. Few objections were received from patients, partly because the devices used were similar, though for a small number of patients some dexterity issues with the new device were identified and addressed.

Carbon footprint considerations

Carbon footprint considerations

A further consideration was the impact of change on the Health Board’s commitment to reducing its carbon footprint, where possible. However, as the move was from one dry powder inhaler to another, there was no significant environmental impact.

Fixkoh delivered significant cost savings to the NHS

Conclusion and main outcomes

The project demonstrated that a pro-active approach to medicines management, initiated and adopted by the Health Board, delivered significant cost savings to the NHS and also supported the Health Board’s commitment to pharmacotherapy (prioritising workforce issues and support for GP workloads).

Download Full Case Study (PDF)

Fixkoh Airmaster

Therapeutically equivalent to Seretide® Accuhaler® 2 for both formulation and device characteristics, Fixkoh Airmaster™ offers:

✓ A COST-EFFECTIVE salmeterol/fluticasone DPI range3
✓ All THREE strengths of ICS in the same device-type4,5,6
✓ Implementation SUPPORT for you and your patients

Request more information or demo devices

References

1. Pharmacy Management Journal. Available here. Access date: August 2023.

2. Swedish Medical Products Agency. Public Assessment Report: Scientific discussion. Sipova Airmaster. 2019. Available here. Access date: August 2023.

3. NICE BNF online. Fluticasone with Salmeterol. Medicinal forms. Available here.  Access date: August 2023.

4. Fixkoh Airmaster 50mcg/100mcg SmPC. Available here. Access date: August 2023.

5. Fixkoh Airmaster 50mcg/250mcg SmPC. Available here. Access date: August 2023.

6. Fixkoh Airmaster 50mcg/500mcg SmPC. Available here. Access date: August 2023.

Seretide® and Accuhaler® are registered trademarks of the GlaxoSmithKline group of companies.

UK-FIXK-88(4) | August 2023

Let's stay connected
icon

Fixkoh Airmaster

salmeterol xinafoate/fluticasone propionate

The information on this site is suitable for and solely intended for UK healthcare professionals. This site contains promotional information.

I confirm I am a UK healthcare professional

UK patients who have been prescribed Fixkoh Airmaster™

Are you a UK patient who has been prescribed Fixkoh Airmaster™ by a UK healthcare professional?

Visit our patient web site

All other visitors

Please view the Summary of Product Characteristics

 

UK-FIXK-50(1) | June 2024